

2018 PD THERAPEUTICS CONFERENCE

The Michael J. Fox Foundation for Parkinson's Research
12th Annual Parkinson's Disease Therapeutics Conference

October 25, 2018
New York, NY

CONFERENCE PROGRAM

All presentations are followed by Q&A.

7:45

BREAKFAST

8:30 – 9:00

WELCOME BY TODD SHERER, PhD AND CAROLE HO, MD

9:00 – 11:05

EMERGING TARGETS AND CONVERGING BIOLOGY IN PARKINSON'S

9:00 – 9:25

SUZANNE PFEFFER, PhD, Stanford University

"Linking Rab GTPases to Parkinson's"

9:25 – 9:50

NICHOLAS THOMAS HERTZ, PhD, Mitokinin, LLC

"Characterization of Novel PINK1 Neo-Substrate Amplifiers"

9:50 – 10:15

SAAR GILL, MD, PhD, University of Pennsylvania

"Genetically Engineered T cells for the Treatment of Parkinson's Disease"

10:15 – 10:40

JULIE ANDERSEN, PhD, Buck Institute for Research on Aging

"Determining the Potential Role of Alpha-synuclein Aggregates as Inducers of Astrocytic Senescence"

10:40 – 11:05

DAVID CRAIG, PhD, University of Southern California

"Longitudinal Small RNA and Whole Transcriptome Sequencing for Over 1,500 Individuals Across 4,600 Whole-blood Samples as Part of the Parkinson's Progression Markers Initiative"

11:05 – 11:35

NETWORKING BREAK/POSTER VIEWING

11:35 – 12:25

BIOMARKERS AND OUTCOME MEASURES (PART I)

11:35 – 12:00

KATHLEEN POSTON, MD, MS, Stanford University

"Recent Advances in MRI for Disease Progression in PD"

12:00 – 12:25

BASTIAAN BLOEM, MD, PhD, Radboud University Medical Center

"Wearable Technologies to Study Parkinson's at Home"



12:25 – 1:25 LUNCH/POSTER VIEWING

1:25 – 2:45 BIOMARKERS AND OUTCOME MEASURES (PART 2)

- 1:25 – 1:55 **UN JUNG KANG, MD, Columbia University**
"Comparative Study of Assays to Detect Oligomerization of α -synuclein by CSF Seeding in BioFIND"
- 1:55 – 2:20 **LANA CHAHINE, MD, University of Pittsburgh**
"Where and When to Look? Results from the Systemic Synuclein Sampling Study (S4)"
- 2:20 – 2:45 **ANDREW SIDEROWF, MD, MSCE, University of Pennsylvania**
KENNETH MAREK, MD, The Institute for Neurodegenerative Disorders
"New Initiatives in PPMI: Thinking Bigger"
-

2:45 – 3:15 NETWORKING BREAK/POSTER VIEWING

3:15 – 4:15 HOT TOPICS IN PARKINSON'S DISEASE RESEARCH

- 3:15 – 3:45 **MATTHEW TROYER, MD, Denali Therapeutics**
"Safety, Tolerability, and Target Engagement Demonstrated in a Phase 1 Study of a LRRK2 Inhibitor (DNL201) in Healthy Young and Elderly Participants"
- 3:45 – 4:15 **RAYMOND J. TESI, MD, INmuneBio**
"It's the Immunology, Not the Pathology..."
-

4:15 – 4:30 CLOSING REMARKS

4:30 – 6:00 COCKTAIL RECEPTION/POSTER VIEWING

